Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90024, United States
Springfield, Massachusetts 01107, United States
Philadelphia, Pennsylvania 19102, United States
Capital Federal, Buenos Aires 1425, Argentina
Capital Federal, Buenos Aires C1155APP, Argentina
Innsbuck, 6020, Austria
Porto Alegre/rs, Rio Grande do Sul 90035, Brazil
Campinas/sp, São Paulo 13083, Brazil